ReviewTuberculosis and respiratory diseases2022
Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria.
Review in Tuberculosis and respiratory diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Adverse Drug Reaction to Linezolid in Drug-Resistant Tuberculosis: A Systematic Review.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Adverse effects of linezolid in the treatment of drug-resistant tuberculosis: a scoping review.Breathe (Sheffield, England) · 2026Review
- Growth Differentiation Factor-15 Could Predict Decreased Hemoglobin in Tuberculosis Treated With Linezolid-Containing Regimen.The clinical respiratory journal · 2026Article
- Post-tuberculosis Health: A Holistic Perspective on Multisystem Sequelae and Long-Term Wellbeing.Tuberculosis and respiratory diseases · 2026Article
- A Short-Course Regimen Containing Delamanid, Bedaquiline and Linezolid for the Treatment of Drug-Resistant Tuberculosis: A Retrospective Study from China.Infection and drug resistance · 2026Article
- Linezolid Related Adverse Effects in Different Populations: A Review.Current drug safety · 2026Review
- The ameliorative effects ofOpen veterinary journal · 2025Article
- Pharmacokinetics and hematologic toxicity of linezolid in children: a prospective, two-center cohort study.Antimicrobial agents and chemotherapy · 2025Article
- Deciphering linezolid-induced hematologic toxicity: Targeting TOP2A and TOP2B via its primary metabolite PNU142586.Science advances · 2025Article
- Article
- Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- The protective role of vitamin C against linezolid-induced hepato-renal toxicity in a rat model.Frontiers in pharmacology · 2025Article
- Therapeutic Drug Monitoring of Linezolid in Drug-Resistant Tuberculosis Patients: Clinical Factors and Hematological Toxicities.Infection and drug resistance · 2024Article
- Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Antimicrobial Synergistic Effects of Linezolid and Vancomycin with a Small Synthesized 2-Mercaptobenzothiazole Derivative: A Challenge for MRSA Solving.Molecules (Basel, Switzerland) · 2023Article
- Nanosized Drug Delivery Systems to Fight Tuberculosis.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Multidrug-resistant tuberculosis (MDR-TB) is caused by an organism that is resistant to both rifampicin and isoniazid. Extensively drug-resistant TB, a rare type of MDR-TB, is caused by an organism that is resistant to quinolone and one of group A TB drugs (i.e., linezolid and bedaquiline). In 2018, the World Health Organization revised the groupings of TB medicines and reclassified linezolid as a group A drug for the treatment of MDR-TB. Linezolid is a synthetic antimicrobial agent in the oxazolidinone class. Although linezolid has a good efficacy, it can cause substantial adverse events, especially hematologic toxicity. In both TB infection and linezolid mechanism of action, mitochondrial dysfunction plays an important role. In this concise review, characteristics of linezolid as an anti-TB drug are summarized, including its efficacy, pathogenesis of hematologic toxicity highlighting mitochondrial dysfunction, and the monitoring and management of hematologic toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.